Outcomes may improve with ibrutinib in chronic lymphocytic leukemia
First-line ibrutinib is associated with better outcomes than chemoimmunotherapy among patients with chronic lymphocytic leukemia (CLL), according to a study published online May 13 in Clinical Lymphoma, Myeloma & Leukemia.
Jun 21, 2024
0
2